Viability and engraftment of hematopoietic progenitor cells after long-term cryopreservation: effect of diagnosis and percentage dimethyl sulfoxide concentration |
| |
| Authors: | Muthu Veeraputhiran John W Theus Gina Pesek Bart Barlogie Michele Cottler-Fox |
| |
| Institution: | 1. Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA;2. Myeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA;1. University of Utah Cell Therapy and Regenerative Medicine Facility, Salt Lake City, Utah, USA;2. University of Utah Division of Hematology & Hematologic Malignancies, Salt Lake City, Utah, USA;1. Department of Medical Oncology, Harvard School of Public Health, Boston, MA;2. Department of Data Science, Dana-Farber Cancer Institute, Harvard School of Public Health, Boston, MA;3. Department of Medicine, Brigham and Women''s Hospital, Boston, MA;1. Institute of Beijing Animal Science and Veterinary, Chinese Academy of Agricultural Science, Beijing, 100193, China;2. Department of Life Science, Department of laboratory medicine, Bengbu Medical College, Bengbu, 233030, China;3. Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin, 150001, China |
| |
| Abstract: | Background aimsWe carried out a retrospective analysis of viability by diagnosis and dimethyl sulfoxide (DMSO) concentration in patients who had undergone autologous transplants using hematopoietic progenitor cells (HPC) after long-term storage (up to 17.8 years).MethodsViability was tested using flow cytometry for HPC that were harvested and preserved using a controlled rate freezer and 5% or 10% DMSO with human serum albumin, then stored in liquid nitrogen. Data from 262 samples were analyzed (249 myeloma patients and 13 other diagnoses): 100 consecutively thawed samples with a storage time of <1 year (all 10% DMSO), 50 consecutive samples stored for 1–4.9 years (10% DMSO), 50 samples stored for 5–9 years (5% DMSO) and all samples stored and used for transplant after >9 years (60 samples, 5% DMSO; two samples, 10% DMSO).ResultsNo statistically significant difference in viability between the 5% DMSO and 10% DMSO groups was observed (P = 0.08), so the 1–4.9 years and 5–9 years were combined and the three groups (<1 year, 1–9 years and >9 years) were compared using an anova test. There was no difference in viability based on cryostorage period (P = 0.23) or between myeloma and other diagnoses (P = 0.45). No difference was seen in time to White blood cell (WBC) engraftment (P = 0.10) or to platelet engraftment between groups (P = 0.52).ConclusionsThese data suggest that long-term storage in 5% DMSO and human serum albumin is safe. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
